title: Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
abstract: OBJECTIVE
  To evaluate the prevalence of antibodies to hepatitis C virus and serological markers for hepatitis B virus infection in patients with HIV.
  
  
  METHODS
  Cross sectional survey.
  
  
  METHODS
  Aquitaine, southwestern France, 1991-94.
  
  
  METHODS
  1935 HIV positive patients seen at least once since June 1991.
  
  
  METHODS
  Presence of antibodies to hepatitis C virus were detected by second or third generation enzyme linked immunosorbent assay (ELISA) and recombinant immunoblot assay (RIBA) and markers for hepatitis B virus detected by ELISA.
  
  
  RESULTS
  The prevalence was 42.5% (823) for antibodies to hepatitis C virus, 56.4 (507) for antibodies to hepatitis B core antigen, 6.9% (133) for hepatitis B surface antigen, 30.2% (584) for antibodies to hepatitis B core and surface antigen with no detectable surface antigen, 26.2% (507) for antibodies to core antigen only, and 4.8% (92) for antibodies to surface antigen only. The prevalence of antibodies to hepatitis C virus was 86.1% (726/843) in subjects who had bloodborne HIV infection and 7.3% (66/899) in those with sexually acquired infection. The prevalence of markers for hepatitis B was higher among homosexuals than in the other groups of patients, except for antibodies to surface antigen alone. The relation between markers for hepatitis B and hepatitis C virus was negative among men but positive among women.
  
  
  CONCLUSIONS
  The results favour the hypothesis that hepatitis C virus is sexually transmitted much less commonly than either HIV or hepatitis B virus.
authors.affiliation: Unité INSERM No 330, Université de Bordeaux II, France.
authors.forename: F
authors.initials: F
authors.lastname: Saillour
authors.forename: F
authors.initials: F
authors.lastname: Dabis
authors.forename: M
authors.initials: M
authors.lastname: Dupon
authors.forename: D
authors.initials: D
authors.lastname: Lacoste
authors.forename: P
authors.initials: P
authors.lastname: Trimoulet
authors.forename: P
authors.initials: P
authors.lastname: Rispal
authors.forename: E
authors.initials: E
authors.lastname: Monlun
authors.forename: J M
authors.initials: JM
authors.lastname: Ragnaud
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: J L
authors.initials: JL
authors.lastname: Pellegrin
authors.forename: H
authors.initials: H
authors.lastname: Fleury
authors.forename: P
authors.initials: P
authors.lastname: Couzigou
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology; D015415:Biomarkers; D002353:Carrier State; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005602:France / Q000453:epidemiology; D006509:Hepatitis B / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D006510:Hepatitis B Antibodies / Q000032:analysis; D006512:Hepatitis B Core Antigens / Q000032:analysis / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D018937:Hepatitis C Antibodies / Q000032:analysis*; D006801:Humans; D007163:Immunosorbent Techniques; D008297:Male; D015995:Prevalence; D012737:Sex Factors
chemical_list: D015415:Biomarkers; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies